Ischemic stroke following reversal of dabigatran with idarucizumab in spontaneous subdural hematoma in cerebral venous thrombosis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242967Keywords:
Cerebral venous thrombosis, Dabigatran, Idarucizumab, Spontaneous subdural hematoma, Subdural hematoma, Ischaemic strokeAbstract
Spontaneous subdural hematomas (SDH) are an unusual but potentially devastating complication of oral anticoagulation. Emergency management of subdural hematomas following oral anticoagulant therapy consists of reversal of anticoagulation coupled with surgical evacuation, if indicated. However, the question of reintroducing anticoagulants is a conundrum faced by clinicians. Clinical equipoise remains divergent among neurologists and literature guiding them is sparse. We report a case of spontaneous acute SDH in a middle-aged woman receiving dabigatran for cerebral venous thrombosis (CVT). Dabigatran reversal was achieved with idarucizumab and burr hole evacuation of the SDH was performed successfully. However, the patient suffered left posterior cerebral artery (PCA) territory ischemic stroke during this period, which appears to be a result of reversal of anticoagulant effect of dabigatran by idarucizumab. With this case report, we seek to highlight this rare complication of dabigatran therapy in CVT, the effectiveness of idarucizumab in reversing dabigatran action and the risks of interruption of dabigatran therapy with idarucizumab.
References
Aronis KN, Hylek EM. Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants. J Am Heart Assoc. 2018;7(3):e007338.
Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: The Antidote for Reversal of Dabigatran. Circulation. 2015;132(25):2412-22.
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-72.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
King B, Milling T, Gajewski B, Costantini TW, Wick J, Price MA, et al. Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials. Trauma Surg Acute Care Open. 2020;5(1):e000605.
Mirzayan MJ, Calvelli K, Capelle HH, Weigand J, Krauss JK. Subdural Hematoma and Oral Anticoagulation: A Therapeutic Dilemma from the Neurosurgical Point of View. J Neurol Surg A Cent Eur Neurosurg. 2016;77(1):31-5.
Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Stroke. 1995;26:1371-7.
Nassiri F, Hachem LD, Wang JZ, Badhiwala JH, Zadeh G, Gladstone D, et al. Reinitiation of Anticoagulation After Surgical Evacuation of Subdural Hematomas. World Neurosurg. 2020;135:e616-22.
Izaguirre Ávila R, Bahena López JE, Cortina de la Rosa E, Hernández Márquez MÁ. Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America. Eur Heart J Case Rep. 2019;3(2):ytz098.
Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511-20.
